Table 2.

Disease-free survival hazard ratios for NOS3 genotypes among women randomized to CMF or CAF ± tamoxifen and among women not receiving adjuvant therapy

GenotypesTreated (n = 458)Untreated (n = 874)
CensoredFailuresaHR (95% CI)CensoredFailuresaHR (95% CI)
NOS3 −786 T > Cn = 445n = 862
    TT123 (38.2)56 (45.5)1.0230 (37.7)112 (44.4)1.0
    TC154 (47.8)49 (39.8)0.74 (0.50-1.12)278 (45.6)117 (46.4)0.89 (0.68-1.15)
    CC45 (14.0)18 (14.6)0.98 (0.57-1.70)102 (16.7)23 (9.1)0.55 (0.35-0.87)
    Ptrend0.5750.015
    Pinteraction0.089
    TT + TC277 (86.0)105 (85.4)1.0508 (83.3)229 (90.9)1.0
    CC45 (14.0)18 (14.6)1.15 (0.69-1.91)102 (16.7)23 (9.1)0.59 (0.38-0.91)
    Pinteraction0.049
NOS3 894 G > Tn = 438n = 862
    GG154 (48.7)65 (53.3)1.0290 (47.5)132 (52.4)1.0
    GT131 (41.5)36 (29.5)0.71 (0.47-1.08)241 (39.5)101 (40.1)0.97 (0.75-1.26)
    TT31 (9.8)21 (17.2)1.54 (0.94-2.53)79 (13.0)19 (7.5)0.66 (0.41-1.07)
    Ptrend0.5260.171
    Pinteraction0.005
    GG + GT285 (90.2)101 (82.8)1.0531 (87.1)233 (92.5)1.0
    TT31 (9.8)21 (17.2)1.76 (1.10-2.83)79 (13.0)19 (7.5)0.67 (0.42-1.07)
    Pinteraction0.003

NOTE: HR controlling for age, race, menopausal status, time between surgery and registration, and types of treatment among the treated arm.

Abbreviation: aHR, adjusted hazard ratio.